These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16912241)

  • 1. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D supplementation in CKD.
    Martin KJ; González EA
    Clin Nephrol; 2011 Apr; 75(4):286-93. PubMed ID: 21426882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary hyperparathyroidism: pathophysiology and treatment.
    Saliba W; El-Haddad B
    J Am Board Fam Med; 2009; 22(5):574-81. PubMed ID: 19734404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM; Coyne D
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual vitamin D pathways: considerations for adequate supplementation.
    Cronin SC
    Nephrol Nurs J; 2010; 37(1):19-26, 36; quiz 27-8. PubMed ID: 20333900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to treatment of secondary hyperparathyroidism.
    Locatelli F; Limardo M; Pontoriero G
    Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D treatment in chronic kidney disease.
    Andress DL
    Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
    Gutiérrez OM
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxercalciferol treatment of secondary hyperparathyroidism.
    Dennis VC; Albertson GL
    Ann Pharmacother; 2006 Nov; 40(11):1955-65. PubMed ID: 17062838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
    Cunningham J; Locatelli F; Rodriguez M
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):913-21. PubMed ID: 21454719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic kidney disease/bone and mineral metabolism: the imperfect storm.
    Williams ME
    Semin Nephrol; 2009 Mar; 29(2):97-104. PubMed ID: 19371800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypovitaminosis D in chronic kidney disease patients: prevalence and treatment.
    Cuppari L; Garcia-Lopes MG
    J Ren Nutr; 2009 Jan; 19(1):38-43. PubMed ID: 19121769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins do not affect mineral metabolism in chronic kidney disease: a retrospective analysis.
    Ashman N; Banerjee A; Yaqoob MM
    Nephron Clin Pract; 2009; 111(4):c236-9. PubMed ID: 19287183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapies for uremic secondary hyperparathyroidism.
    Torres PU; Prié D; Beck L; Friedlander G
    J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.